Sustainability | December 12, 2025
Granules India receives official 2025 CDP rating
The company had achieved the highest "A" rating in Climate Change
The company had achieved the highest "A" rating in Climate Change
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Subscribe To Our Newsletter & Stay Updated
